Lucitanib for the Treatment of HR+/HER2- Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study.

Rina HuiAlex Pearson Javier Cortes Christine CampbellCamille PoirotHatem A AzimDebora Fumagalli Matteo LambertiniFergus DalyAmal ArahmaniJosé Perez-GarciaPhilippe AftimosPhilippe L BedardLaura XuerebElsemieke D ScheepersMalou VicenteTheodora GouliotiSibylle LoiblSherene LoiMarie-Jeanne PierratNicholas C TurnerFabrice AndreCurigliano Giuseppe

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Lucitanib had modest antitumor activity and significant hypertension-related toxicity in patients with HR + /HER2 - MBC. Although based on small sample sizes, exploratory biomarker analyses suggested that patients with high FGFR1 amplification or expression might derive greater benefit.

Keyphrases

phase ii
metastatic breast cancer
clinical trial
open label
blood pressure
poor prognosis
oxidative stress
randomized controlled trial
nucleic acid
placebo controlled
combination therapy